Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial
NCT05378113 · Emory University · PHASE2 · terminated · last registry update 2026-04-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to enrollment challenges following the relocation of orthopedic procedures to a different hospital.” | – | Registry record, Emory University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR3A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Phase 3 first posted: Shanghai Mental Health Center, [Phase 1] Clozapine + [Phase 1] Aripiprazole (NCT07918222)
- 2026-10-05Also stopped (withdrawn): Health Sciences North Research Institute, Oral metoclopramide and ibuprofen + Intravenous metoclopramide and ketorolac (NCT05983354)
- 2026-08-03Phase 3 first posted: Chengdu Kanghong Pharmaceutical Group Co., Ltd., KH607 tablets + Vortioxetine Hydrobromide Tablets (NCT07741331)
- 2026-05-28Results posted on the registry: Jennifer Holder-Murray, Neuraxial Analgesia + Regional Block 1: Paravertebral (NCT04606264)
- 2026-05-22Also stopped (terminated): OrthoCarolina Research Institute, Inc., a drug against HTR3A (NCT02202369)
- 2026-05-15Results posted on the registry: Montefiore Medical Center, Dexamethasone + Metoclopramide 10mg (NCT04799015)
- 2026-05-14Phase 3 first posted: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal, Ondansetron hydrochloride 8 mg IV Q8H + 0.9 % Normal Saline 10 ml (NCT07588217)
- 2026-03-13Results posted on the registry: Beth Israel Deaconess Medical Center, Ondansetron + Dexamethasone (NCT05692245)
- 2026-03-09Results posted on the registry: National Cancer Institute (NCI), E7 TCR cells + Aldesleukin (NCT02858310)
- 2025-12-19Results posted on the registry: National Cancer Institute (NCI), Aldesleukin + Cyclophosphamide (NCT01319565)
- 2025-12-05Results posted on the registry: M.D. Anderson Cancer Center, Zofran + Dexamethasone (NCT02473042)
- 2025-12-02Results posted on the registry: National Cancer Institute (NCI), IL-2 (Aldesleukin) + Cyclophosphamide (NCT05035407)
- 2025-12-02Also stopped (terminated): National Cancer Institute (NCI), IL-2 (Aldesleukin) + Cyclophosphamide (NCT05035407)
- 2025-11-17Results posted on the registry: Hackensack Meridian Health, Prophylactic use of ibuprofen and ondansetron post misoprostol administration + Use of ibuprofen and ondansetron at symptom onset post misoprostol administration (NCT05819619)
- 2025-11-17Also stopped (terminated): Hackensack Meridian Health, Prophylactic use of ibuprofen and ondansetron post misoprostol administration + Use of ibuprofen and ondansetron at symptom onset post misoprostol administration (NCT05819619)
- 2025-10-29Results posted on the registry: Helsinn Healthcare SA, NEPA (300mg netupitant/0.5mg palonosetron) + Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV) (NCT04817189)
- 2025-10-06Phase 3 first posted: Affiliated Hospital of Qinghai University, Olanzapine + Metoclopramide (NCT07208305)
- 2025-09-25Results posted on the registry: University of Rochester NCORP Research Base, Dexamethasone + Netupitant/Palonosetron Hydrochloride (NCT03367572)
- 2025-09-11Also stopped (terminated): DAS-MG, Inc, DAS-001 (NCT04226170)
- 2025-09-08Also stopped (terminated): Assistance Publique - Hôpitaux de Paris, Clorazepate Dipotassium + Placebo (NCT04726592)
- 2025-08-15Phase 3 first posted: The First Affiliated Hospital of Xinxiang Medical College, Medroxyprogesterone acetate oral suspension + high antiemetic regimen (NCT07124195)
- 2025-08-14Results posted on the registry: Washington University School of Medicine, Ondansetron 16 mg with Tariquidar + Ondansetron 16 mg with Placebo (NCT04603066)
- 2025-07-29Also stopped (withdrawn): United States Naval Medical Center, Portsmouth, Haloperidol + Metoclopramide 10mg (NCT02098499)
- 2025-07-28Results posted on the registry: University of Texas Southwestern Medical Center, Rocuronium + Sugammadex (NCT06225466)
- 2025-07-23Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLM2010 for injection；dexamethasone + fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone (NCT07081256)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision